Guiyang Xintian Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.00%

Guiyang Xintian Pharmaceutical Co Ltd (002873) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002873 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥102.45K
≈ $14.99K USD Cash + Short-term Investments

Total Assets

CN¥2.09 Billion
≈ $306.26 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Guiyang Xintian Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Guiyang Xintian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guiyang Xintian Pharmaceutical Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥102.45K 0.0%
Total Liquid Assets CN¥102.45K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Guiyang Xintian Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Guiyang Xintian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guiyang Xintian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.10%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 4.52%
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 35.56%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Guiyang Xintian Pharmaceutical Co Ltd (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Guiyang Xintian Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.01% CN¥118.68K
≈ $17.37K
CN¥1.95 Billion
≈ $285.42 Million
+0.00pp
2023-12-31 0.00% CN¥94.33K
≈ $13.80K
CN¥1.91 Billion
≈ $279.76 Million
0.00pp
2022-12-31 0.01% CN¥111.58K
≈ $16.33K
CN¥1.84 Billion
≈ $269.81 Million
-5.24pp
2021-12-31 5.25% CN¥80.00 Million
≈ $11.71 Million
CN¥1.52 Billion
≈ $223.07 Million
-2.43pp
2020-12-31 7.68% CN¥118.00 Million
≈ $17.27 Million
CN¥1.54 Billion
≈ $224.76 Million
--
pp = percentage points

About Guiyang Xintian Pharmaceutical Co Ltd

SHE:002873 China Biotechnology
Market Cap
$360.77 Million
CN¥2.47 Billion CNY
Market Cap Rank
#14185 Global
#4460 in China
Share Price
CN¥10.10
Change (1 day)
+2.85%
52-Week Range
CN¥8.85 - CN¥15.19
All Time High
CN¥103738.98
About

Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more